CMV pp65 modulators(Cytomegalovirus pp65 Antigen modulators), EphA2 antagonists(Ephrin type-A receptor 2 antagonists), survivin inhibitors(Baculoviral IAP repeat-containing protein 5 inhibitors)

+ [1]

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

Glioblastoma Multiforme

Inactive Indication-

Originator Organization

Duke University

Active Organization

National Cancer Institute

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with P30-EPS vaccine(Duke University)

NCT05283109 / RecruitingPhase 1IIT

ETAPA I: Evaluation of Tumor Associated P30-Peptide Antigen I; A Pilot Trial of Peptide-based Tumor Associated Antigen Vaccines in Newly Diagnosed, Unmethylated, and Untreated Glioblastoma (GBM)

This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.

Start Date30 Aug 2023

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with P30-EPS vaccine(Duke University)

100 Translational Medicine associated with P30-EPS vaccine(Duke University)

100 Patents (Medical) associated with P30-EPS vaccine(Duke University)

Literatures (Medical) associated with P30-EPS vaccine(Duke University)

01 Jul 1994·Avian DiseasesQ4 · AGRICULTURAL & FORESTRY SCIENCE

Response of Specific-Pathogen-Free Turkeys to Vaccines Derived from Marble Spleen Disease Virus and Hemorrhagic Enteritis Virus

Q4 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: J. M. Sharma

Tissue-culture-propagated marble spleen disease virus (MSDV-TC) and two preparations of spleen homogenate (MSDV-SH and MSDV-SH-TC) were compared as anti-hemorrhagic enteritis virus (HEV) vaccines in specific-pathogen-free turkeys. Both types of vaccines spread horizontally among turkeys, induced anti-HEV antibodies, and protected turkeys against challenge with virulent HEV. Antibody development and horizontal spread of virus occurred earlier in turkeys given MSDV-SH or MSDV-SH-TC than in those given MSDV-TC. Virulent HEV was serially passed in MDTC-RP19 cells. The 30th passage virus (HEV-P30) was nonpathogenic for turkeys but was immunogenic. Turkeys exposed to HEV-P30 had viral antigen in the spleen, developed neutralizing antibodies, and resisted virulent HEV. The principal difference between MSDV-TC and HEV-P30 vaccines was that MSDV-TC caused well-defined splenomegaly in turkeys, whereas HEV-P30 protected turkeys without causing spleen enlargement.

Nanoscale Advances

A mucus-inspired solvent-free carbon dot-based nanofluid triggers significant tribological synergy for sulfonated h-BN reinforced epoxy composites

Article

Author: Gong, Ping ; Nishimura, Kazuhito ; Jiang, Nan ; Jiao, Chengcheng ; Atkin, Rob ; Wang, Yandong ; Li, Hua ; Zhao, Haichao ; Yu, Jinhong ; Chen, Huanyi ; Cai, Tao ; Ruan, Xinxin ; Yang, Feng

The tribological properties of the epoxy were significantly improved due to the tribological synergy of biomimetic F-CDs and sulfonated h-BN.

Vaccines

Local Enrichment with Convergence of Enriched T-Cell Clones Are Hallmarks of Effective Peptide Vaccination against B16 Melanoma

Article

Author: Samitova, Alina Faritovna ; Izosimova, Anna Vyacheslavovna ; Ryzhichenko, Ekaterina Olegovna ; Myshkin, Mikhail Yurevich ; Shagina, Irina Aleksandrovna ; Yuzhakova, Diana Vladimirovna ; Myalik, Daria Sergeevna ; Britanova, Olga Vladimirovna ; Shabalkina, Alexandra Valerievna ; Barsova, Ekaterina Vladimirovna ; Shurganova, Elizaveta Viktorovna ; Sharonov, George Vladimirovich

Background: Some peptide anticancer vaccines elicit a strong T-cell memory response but fail to suppress tumor growth. To gain insight into tumor resistance, we compared two peptide vaccines, p20 and p30, against B16 melanoma, with both exhibiting good in vitro T-cell responses but different tumor suppression abilities. Methods: We compared activation markers and repertoires of T-lymphocytes from tumor-draining (dLN) and non-draining (ndLN) lymph nodes for the two peptide vaccines. Results: We showed that the p30 vaccine had better tumor control as opposed to p20. p20 vaccine induced better in vitro T-cell responsiveness but failed to suppress tumor growth. Efficient antitumor vaccination is associated with a higher clonality of cytotoxic T-cells (CTLs) in dLNs compared with ndLNs and the convergence of most of the enriched clones. With the inefficient p20 vaccine, the most expanded and converged were clones of the bystander T-cells without an LN preference. Conclusions: Here, we show that the clonality and convergence of the T-cell response are the hallmarks of efficient antitumor vaccination. The high individual and methodological dependencies of these parameters can be avoided by comparing dLNs and ndLNs.

100 Deals associated with P30-EPS vaccine(Duke University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma Multiforme	Phase 1	US	National Cancer Institute	30 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

P30-EPS vaccine(Duke University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation